21 October 2021: Articles
Treatment of Severe Immune Thrombocytopenic Purpura Associated with COVID-19
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Nayab Ahmed A* , Abdullah Asreb E , Rosemary Chofor E , Achenef Melese ADOI: 10.12659/AJCR.932557
Am J Case Rep 2021; 22:e932557
Figure 1. The graph depicts the trend in the patient’s platelet count. She was started on i.v. immunoglobulin 1 g/kg for 2 days along with prednisone 60 mg on day 1of hospital admission (indicated by the first arrow). The platelet count continued to fluctuate. Rituximab 375 mg/m2 was added to her regimen on day 6 of hospital admission (initiation point indicated by second arrow) due to a continued downward trend of platelet count. Prednisone was also continued.